for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eiger Biopharmaceuticals Inc

EIGR.OQ

Latest Trade

11.49USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

4.62

 - 

15.82

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.49
Open
--
Volume
--
3M AVG Volume
8.56
Today's High
--
Today's Low
--
52 Week High
15.82
52 Week Low
4.62
Shares Out (MIL)
29.24
Market Cap (MIL)
336.00
Forward P/E
-7.90
Dividend (Yield %)
--

Next Event

Q3 2020 Eiger BioPharmaceuticals Inc Earnings Release

Latest Developments

More

Eiger Biopharmaceuticals Says May Offer And Sell Shares Of Common Stock Having Aggregate Offering Price Of Up To $50 Mln From Time To Time

Eiger Biopharmaceuticals Reports Second Quarter 2020 Financial Results And Provides Business Update

Eiger Biopharmaceuticals Announces FDA Acceptance Of NDA For Filing With Priority Review Of Zokinvy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eiger Biopharmaceuticals Inc

Eiger BioPharmaceuticals Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing drugs for serious diseases. Its product candidate pipeline includes programs, including Lonafarnib (LNF), Peginterferon Lambda (lambda), LNF in Progeria and Progeroid Laminopathies (PL), Avexitide. LNF is an orally bioavailable, farnesylation inhibitor in Phase-III clinical trials for Hepatitis Delta Virus (HDV) infection. Lambda is a late-stage, type III interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. It is also developing lonafarnib for treatment of Progeria and Progeroid Laminopathies. Avexitide is a peptide that it is being developed as a treatment for Post-Bariatric Hypoglycemia (PBH). Avexitide is also being developed for Congenital Hyperinsulinism (CHI).

Industry

Biotechnology & Drugs

Contact Info

2155 Park Blvd

PALO ALTO, CA

94306-1543

United States

+1.650.2799845

http://www.eigerbio.com/

Executive Leadership

Thomas J. Dietz

Independent Chairman of the Board

David A. Cory

President, Chief Executive Officer, Director

Sriram Ryali

Chief Financial Officer

Eldon C. Mayer

Executive Vice President, Chief Commercial Officer

Stephana Eilene Patton

Chief Compliance Officer, General Counsel, Corporate Secretary

Key Stats

1.00 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-4.860

2018

-3.820

2019

-3.080

2020(E)

-1.398
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
5.35
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
52.62
LT Debt To Equity (MRQ)
47.01
Return on Investment (TTM)
-63.98
Return on Equity (TTM)
-56.00

Latest News

Latest News

BRIEF-Eiger Biopharmaceuticals Announces FDA Acceptance Of NDA For Filing With Priority Review Of Zokinvy

* EIGER BIOPHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NDA FOR FILING WITH PRIORITY REVIEW OF ZOKINVY™ (LONAFARNIB) FOR TREATMENT OF PROGERIA AND PROGEROID LAMINOPATHIES

BRIEF-Eiger Biopharmaceuticals Q1 Loss Per Share $0.62

* EIGER BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Eiger BioPharmaceuticals Announces EMA Validation Of Lonafarnib MAA

* EIGER BIOPHARMACEUTICALS INC - ANNOUNCES EMA VALIDATION OF LONAFARNIB MAA FOR TREATMENT OF PROGERIA AND PROGEROID LAMINOPATHIES Source text for Eikon: Further company coverage:

BRIEF-Eiger Biopharma Sees COVID-19 Pandemic Delaying D-LIVR Study Enrollment

* EIGER BIOPHARMACEUTICALS PROVIDES UPDATE ON CLINICAL DEVELOPMENT ACTIVITIES AND BUSINESS OPERATIONS DURING COVID-19 PANDEMIC

BRIEF-Eiger Biopharmaceuticals Announces Proposed Public Offering Of Common Stock

* EIGER BIOPHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Progeria Research Foundation Announces Collaboration, Supply Agreement With Eiger Biopharma

* PROGERIA RESEARCH FOUNDATION ANNOUNCES COLLABORATION AND SUPPLY AGREEMENT WITH EIGER BIOPHARMACEUTICALS Source text for Eikon: Further company coverage:

BRIEF-Eiger Announces Expanded License Agreement With Merck For Lonafarnib

* EIGER ANNOUNCES EXPANDED LICENSE AGREEMENT WITH MERCK FOR INVESTIGATIONAL CANDIDATE LONAFARNIB AND COLLABORATION WITH THE PROGERIA RESEARCH FOUNDATION (PRF) Source text for Eikon: Further company coverage:

BRIEF-Eiger Biopharmaceuticals Reports First Quarter 2018 Financial Results

* EIGER BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Eiger Biopharmaceuticals Sees Phase 3 D-Livr Trial Starting In Second Half 2018​

* EIGER BIOPHARMACEUTICALS ANNOUNCES POSITIVE GUIDANCE FOLLOWING FDA MEETING ON HEPATITIS DELTA VIRUS REGISTRATION PROGRAM

BRIEF-Eiger Biopharmaceuticals Q4 Loss Per Share $1.11

* EIGER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Eiger to abandon blood pressure drug after trial failure

Eiger BioPharmaceuticals Inc said on Tuesday it would stop development of its blood pressure drug after it failed in a mid-stage study, sending its shares plunging about 46 percent.

Eiger BioPharma abandons blood pressure drug after failed study

Eiger BioPharmaceuticals Inc said on Tuesday it would stop testing its drug ubenimex for the treatment of pulmonary arterial hypertension, a type of high blood pressure, after the drug failed to meet the main goal in a mid-stage study.

BRIEF-Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal

* EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT

BRIEF-Eiger Biopharma Files For Mixed Shelf Of Up To $125 Mln

* EIGER BIOPHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $125 MILLION - SEC FILING Source text: (http://bit.ly/2nUkpvR) Further company coverage:

BRIEF-‍Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals​

* Prosight Management reports a 6.9 percent passive stake in Eiger Biopharmaceuticals as of Oct 31 - SEC filing Source text: (http://bit.ly/2mbmToK) Further company coverage:

BRIEF-Eiger Biopharmaceuticals reports Q3 loss per share $1.10

* Eiger Biopharmaceuticals reports third quarter 2017 financial results

BRIEF-Eiger Biopharmaceuticals closes public offering

* Eiger Biopharmaceuticals announces closing of public offering of common stock and exercise in full of underwriter's option to purchase additional shares Source text for Eikon: Further company coverage:

BRIEF-EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

* EIGER BIOPHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Eiger BioPharmaceuticals announces proposed public offering of common stock

* Eiger BioPharmaceuticals announces proposed public offering of common stock

BRIEF-Eiger appoints Evan Loh to its Board of Directors

* Eiger announces appointment of biopharmaceutical industry veteran Evan Loh, MD to its Board of Directors Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up